Boehringer's COPD spray Combivent Respimat gets FDA approval

10/9/2011 | Family Practice News · Medscape (free registration)

The FDA approved Combivent Respimat Inhalation Spray, Boehringer Ingelheim's treatment for patients with chronic obstructive pulmonary disease. The therapy comprises albuterol sulfate and ipratropium bromide. It is a "suitable alternative" to chlorofluorocarbon-based Combivent inhalation aerosol, which will be phased out after Dec. 31, 2013, according to an FDA statement.

View Full Article in:

Family Practice News · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC